Clerici M, Landay AL, Kessler HA, Phair JP, Venzon DJ, Hendrix CW, Lucey DR, Shearer GM.
J Infect Dis. 1992 Oct;166(4):723-30. doi: 10.1093/infdis/166.4.723.
Peripheral blood mononuclear cells from 12 asymptomatic patients infected with immunodeficiency virus (HIV) and 4 patients with AIDS were analyzed before and during therapy with zidovudine for T helper cell (Th) function. Th function improved by more than fourfold...
Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, Bryson YJ, Dankner WM, Livingston RA, Connor EM.
N Engl J Med. 1994 Nov 03;331(18):1181-7. doi: 10.1056/NEJM199411033311802.
BACKGROUND: Serious bacterial infections are common in children infected with the human immunodeficiency virus (HIV). Studies performed before zidovudine became standard therapy found that intravenous immune globulin decreases the number of serious bacterial infections in these children. We designed...
Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J.
N Engl J Med. 1993 Jul 29;329(5):297-303. doi: 10.1056/NEJM199307293290501.
BACKGROUND: Zidovudine therapy is of benefit in the treatment of symptomatic and asymptomatic human immunodeficiency virus (HIV) infection in persons with CD4+ cell counts of less than 500 per cubic millimeter. The efficacy, safety, and duration of benefit of...
Miró JM, Antela A, Arrizabalaga J, Clotet B, Gatell JM, Guerra L, Iribarren JA, Laguna F, Moreno S, Parras F, Rubio R, Santamaría JM, Viciana P.
Enferm Infecc Microbiol Clin. 2000 Aug-Sep;18(7):329-51.
OBJECTIVE: To update the recommendations for antiretroviral therapy in adult HIV-infected persons according to the new scientific advances and the existence of new antiretroviral drugs in the last two years.METHODS: The antiretroviral therapy recommendations have been condensed by a...
Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, Hirschel B, Lange J, Squires K, Rawlins S, Meibohm A, Leavitt R.
J Infect Dis. 1999 Sep;180(3):659-65. doi: 10.1086/314948.
A randomized, double-blind, multicenter study of indinavir, zidovudine, and lamivudine was conducted in 320 adults with human immunodeficiency virus type 1 (HIV-1) infection,
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA.
N Engl J Med. 1997 Sep 11;337(11):725-33. doi: 10.1056/NEJM199709113371101.
BACKGROUND: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and...
[No authors listed]
Clin Investig. 1994 Jan;72(2):111-6.
While efficacy of zidovudine (ZDV) in the acquired immunodeficiency syndrome (AIDS) is well established, the issue of survival after early ZDV treatment is still controversial. To assess survival benefits of ZDV treatment prior to AIDS, as compared to treatment...
Moyle GJ, Bouza E, Antunes F, Smith D, Harris R, Warburg M, Walker M.
Antivir Ther. 1997 Dec;2(4):229-36.
OBJECTIVE: To assess the safety and clinical and immunological activity of zalcitabine/zidovudine combination therapy compared with zidovudine monotherapy in persons with no or limited antiretroviral experience and CD4 counts of 300-500 cells/mm3.DESIGN AND SETTING: A double-blind controlled multi-centre study...
Ayele T, Jarso H, Mamo G.
AIDS Res Ther. 2017 Feb 01;14(1):5. doi: 10.1186/s12981-017-0132-4.
BACKGROUND: Tenofovir (TDF) based regimen was reported to have better immunological outcomes. Unfortunately, there is limited information regarding the immunologic outcome associated with this regimen in Ethiopia, as its routine utilization in this setting begun since 2013.METHODS: A 2...
Moore RD, Keruly J, Richman DD, Creagh-Kirk T, Chaisson RE.
AIDS. 1992 Jul;6(7):671-7.
OBJECTIVE: To describe the natural history of advanced HIV disease in patients treated with zidovudine.DESIGN: Longitudinal, observational study.SETTING: Twelve academic and community-based sites.PATIENTS, PARTICIPANTS: Eight hundred and sixty-three patients with AIDS or AIDS-related complex (ARC) with a CD4+ lymphocyte...
[No authors listed]
Lancet. 1994 Apr 09;343(8902):871-81.
Concorde is a double-blind randomised comparison of two policies of zidovudine treatment in symptom-free individuals infected with human immunodeficiency virus (HIV): (a) immediate zidovudine from the time of randomisation (Imm); and (b) deferred zidovudine (Def) until the onset of...
Fiala M, Swartz J, Teklehaimanot S, Kermani V, Funnye AS, Sayre JW, Gornbein JA.
Lymphology. 1997 Sep;30(3):128-36.
In 60 patients followed from the onset of acquired immunodeficiency syndrome (AIDS) to death, survival was determined by Cox Proportional Hazards Analysis in relationship to seven variables: time-dependent CD4+ and CD8+ peripheral lymphocyte counts, zidovudine treatment, cytomegalovirus (CMV) retinitis,...